BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
Key Highlights
- ➤BridgeBio will present 24-week Phase 3 CALIBRATE encaleret results at ASBMR 2026
- ➤Encaleret data cover patient-reported outcomes and bone turnover in ADH1
- ➤Regional testing events evaluated no-cost cascade genetic testing for at-risk ADH1 relatives
- ➤Infigratinib data show no peripheral FGFR1 inhibition at clinically relevant exposures
- ➤Findings support achondroplasia safety profile observed in children in the PROPEL program
Expert Statements
Erik A. Imel, M.D., Indiana University School of Medicine
“Encaleret Restores Mineral Homeostasis and Increases Bone Turnover in Autosomal Dominant Hypocalcemia Type 1 (ADH1): 24-Week Results from Phase 3 CALIBRATE Trial”
Steven W. Ing, M.D., Ohio State University Wexner Medical Center
“Participant-Reported Changes in Symptoms and Treatment Experience with Encaleret in Autosomal Dominant Hypocalcemia Type 1: 24-Week Findings from the Phase 3 CALIBRATE Trial”
Susan Martin, MSPH, RTI Health Solutions
“Baseline Symptom Burden and Impact on Daily Functioning in Autosomal Dominant Hypocalcemia Type 1: Exit Interview Findings from the Phase 3 CALIBRATE Trial”
Mark Warren, M.D., Physicians East, Greenville, NC
“Family Cascade Genetic Testing for Autosomal Dominant Hypocalcemia Type 1: A Multi-Stakeholder Regional Event Model”
Bhavik Shah, BridgeBio Skeletal Dysplasias
“Lack of Peripheral FGFR1 Inhibition at Clinically Relevant Infigratinib Exposures Supports the Safety Profile Observed in Children with Achondroplasia”
PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional evidence from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) will be shared at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place in Boston, Massachusetts on October 9-12, 2026.
BridgeBio will present the effects of encaleret on patient-reported outcomes and on bone turnover from the Phase 3 CALIBRATE trial. In partnership with the HypoPARAthyroidism Association, BridgeBio will also share findings from regional family cascade genetic testing events that evaluated a proband-initiated model designed to bring no-cost genetic testing and counseling directly to at-risk relatives in their home region.
Get started
Create a free account to read the full story.